JP4714908B2 - 沙棘種子抽出物 - Google Patents
沙棘種子抽出物 Download PDFInfo
- Publication number
- JP4714908B2 JP4714908B2 JP2007501094A JP2007501094A JP4714908B2 JP 4714908 B2 JP4714908 B2 JP 4714908B2 JP 2007501094 A JP2007501094 A JP 2007501094A JP 2007501094 A JP2007501094 A JP 2007501094A JP 4714908 B2 JP4714908 B2 JP 4714908B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- ethyl acetate
- cells
- eosinophils
- apoptosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 210000003979 eosinophil Anatomy 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 19
- 230000006907 apoptotic process Effects 0.000 description 16
- 239000003814 drug Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 101001052494 Xenopus laevis Mitogen-activated protein kinase 1 Proteins 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 206010014950 Eosinophilia Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 241000219315 Spinacia Species 0.000 description 5
- 235000009337 Spinacia oleracea Nutrition 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000002327 eosinophilic effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 239000000043 antiallergic agent Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 210000001132 alveolar macrophage Anatomy 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 2
- 229960004754 astemizole Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- CZNJCCVKDVCRKF-UHFFFAOYSA-N Benzyl sulfate Chemical compound OS(=O)(=O)OCC1=CC=CC=C1 CZNJCCVKDVCRKF-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000004335 respiratory allergy Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
沙棘の種子に対しエタノールによる抽出を2回繰り返し行い、これらの抽出液を合わせ、減圧濃縮して褐色粉末状の抽出物を得るステップ;
前記粉末状抽出物を水に溶解し、エチルエーテル、酢酸エチル、ブタノールを抽出溶媒として、順次それぞれ3回抽出を行うステップ;
エチルエーテル画分を濃縮し、褐色のオイルを得るステップ;
前記褐色のオイルをシリカゲルカラムに付し、酢酸エチルで溶出し、溶出画分を回収するステップ。
前記エタノール浸漬時間は好ましくは12時間とする。
前記酢酸エチルの溶出濃度は好ましくは15%とする。
前記抽出物は、好酸球のアポトーシスを誘発する活性を有する。
前記抽出物は、MBPキナーゼを活性化することができる。
前記抽出物は、過剰な好酸球に起因して生じる様々な疾患に対し、好酸球のアポトーシスを誘発する作用を発揮する。
前記抽出物は、アレルギー性鼻炎に対し、好酸球のアポトーシスを誘発する作用を発揮する。
前記抽出物は、アトピー性気管支喘息に対し、好酸球のアポトーシスを誘発する作用を発揮する。
沙棘種子の抽出物は、好酸球減少作用などの面において優れた効果を示し、過剰な好酸球に起因して生じる様々な疾患に対する効果的な予防と治療に使用できる。すなわち、アレルギー性鼻炎あるいはアトピー性気管支喘息の予防と治療において有効に作用する。アポトーシス誘発剤、抗アレルギー剤、抗炎症薬および健康補助食品として使用できる。
沙棘の種子6.7kgに篩による夾雑物除去などの前処理を行った後、80%エタノール[エタノール:水=8:2(体積比、以下同じ)]55Lにて12時間浸漬抽出する。次いで再度80%エタノール55Lにより抽出を行い、これらの抽出液を合一し、減圧濃縮および真空乾燥を行い、褐色粉末状の抽出物1384.9gを得た。
好酸球性細胞のアポトーシス誘発試験
試験はVermesらの方法(Journal of Immunological Methods,vol.184,P.39−59,1995年)に準拠して行った。好酸球性細胞HL−60細胞を、細胞濃度が1−3×106細胞/mlになるようにRPMI1640培地に浮遊させる。この細胞浮遊液500μlに、濃度が100μg/mlとなるように被検物質(前記実施例1で最終的に回収された画分の1つ)または培地を添加し、37℃、5%CO2の条件下で6時間または24時間培養する。遠心洗浄した後、アネキシンV緩衝液を加え、次いでアネキシンV−FITCを5μl添加する。フローサイトメトリーにより、アネキシンV陽性の細胞をアポトーシス誘発細胞として、全細胞数に対する百分率で評価した。
試験はDe Souzaらの方法(Blood,vol.99,P.3432−3438,2002年)に準拠して行った。好酸球性細胞HL−60細胞を、細胞濃度が1−3×106細胞/mlになるようにRPMI1640培地に浮遊させる。この細胞浮遊液500μlに、濃度が100μg/mlとなるように被検物質または培地を添加し、37℃、5%CO2の条件下で6時間または24時間培養する。遠心洗浄した後、可溶化緩衝液を添加して細胞を溶解し、MBP5mg/mlを含有するゲルを用いて電気泳動する。ゲルに対し変性剤除去、リフォールディング処理をした後、32P−ATPで標識し、リン酸化反応を3時間実施する。ゲルを乾燥した後、イメージアナライザーを用いて放射活性を解析する。36kDaにバンドが出現した場合、MBPキナーゼ活性化は陽性(+)とした。
抽出物4は強いアポトーシス誘発活性を有し、これはMBPキナーゼの活性化を伴っていることを確認した。
Claims (4)
- 沙棘種子抽出物の製造方法であって、
沙棘の種子に対しエタノールによる抽出を2回繰り返し行い、該抽出液を合わせ、減圧濃縮して褐色粉末状の抽出物を得るステップと、
前記粉末状抽出物を水に溶解し、エチルエーテル、酢酸エチルおよびブタノールを抽出溶媒として、順次それぞれ3回抽出を行うステップと、
エチルエーテル画分を濃縮し、褐色のオイルを得るステップと、
前記褐色のオイルをシリカゲルカラムに付し、酢酸エチルで溶出し、溶出画分を回収するステップと
を含む方法。 - 前記エタノールの濃度が80%であることを特徴とする請求項1に記載の方法。
- 前記エタノール浸漬時間が12時間であることを特徴とする請求項1に記載の方法。
- 前記酢酸エチルの溶出濃度が15%であることを特徴とする請求項1に記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2004/000172 WO2005084693A1 (fr) | 2004-03-04 | 2004-03-04 | Extrait de la graine de hippophae rhamnoides |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007526260A JP2007526260A (ja) | 2007-09-13 |
JP4714908B2 true JP4714908B2 (ja) | 2011-07-06 |
Family
ID=34916990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007501094A Expired - Fee Related JP4714908B2 (ja) | 2004-03-04 | 2004-03-04 | 沙棘種子抽出物 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4714908B2 (ja) |
CN (1) | CN100402047C (ja) |
WO (1) | WO2005084693A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009082511A1 (en) | 2007-12-20 | 2009-07-02 | Elc Management Llc | Methods and compositions for treating skin |
US9687517B2 (en) | 2007-12-20 | 2017-06-27 | Elc Management Llc | Methods and compositions for treating skin |
JP2013522190A (ja) * | 2010-03-08 | 2013-06-13 | イーエルシー マネージメント エルエルシー | 皮膚に適用するための組成物および方法 |
CN102755359B (zh) * | 2012-07-19 | 2014-04-02 | 中国科学院研究生院 | 一种沙棘提取物及其制备方法与在抑制脂肪酸合酶活性中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6240292A (ja) * | 1985-08-14 | 1987-02-21 | Sankyo Co Ltd | 抗生物質ゾフイマリン |
JPH10120585A (ja) * | 1996-10-15 | 1998-05-12 | Pola Chem Ind Inc | 美白経口投与組成物 |
RU2132183C1 (ru) * | 1998-10-16 | 1999-06-27 | Утешев Даниил Борисович | Мазь для лечения воспалительных и аллергических поражений кожи |
JP2001163792A (ja) * | 1999-12-08 | 2001-06-19 | Koji Tanaka | 滋養強壮健康増進用組成物 |
JP2002212052A (ja) * | 2001-01-15 | 2002-07-31 | Hajime Ito | 外用組成物 |
WO2003084556A1 (fr) * | 2002-04-04 | 2003-10-16 | Kaneka Corporation | Procede de fabrication de composition lipidique contenant des composants hydrophobes de glycyrrhiza |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1060353C (zh) * | 1996-07-02 | 2001-01-10 | 赤峰制药厂 | 一种止咳平喘药物 |
CN1220886A (zh) * | 1997-12-26 | 1999-06-30 | 高文清 | 咳喘胶囊及制作工艺 |
DE20203549U1 (de) * | 2002-03-05 | 2002-10-17 | Eckardt Rainer | Pflege und Heilsalbe zur Behandlung trockener oder entzündeter Nasenschleimhaut |
CN1329043C (zh) * | 2002-08-06 | 2007-08-01 | 山西省林业科学研究院 | 沙棘全果素及其制备方法和用途 |
CN1504467A (zh) * | 2002-12-05 | 2004-06-16 | 河北神兴沙棘研究院 | 沙棘叶总黄酮提取工艺 |
-
2004
- 2004-03-04 WO PCT/CN2004/000172 patent/WO2005084693A1/zh active Application Filing
- 2004-03-04 JP JP2007501094A patent/JP4714908B2/ja not_active Expired - Fee Related
- 2004-03-04 CN CNB200480042278XA patent/CN100402047C/zh not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6240292A (ja) * | 1985-08-14 | 1987-02-21 | Sankyo Co Ltd | 抗生物質ゾフイマリン |
JPH10120585A (ja) * | 1996-10-15 | 1998-05-12 | Pola Chem Ind Inc | 美白経口投与組成物 |
RU2132183C1 (ru) * | 1998-10-16 | 1999-06-27 | Утешев Даниил Борисович | Мазь для лечения воспалительных и аллергических поражений кожи |
JP2001163792A (ja) * | 1999-12-08 | 2001-06-19 | Koji Tanaka | 滋養強壮健康増進用組成物 |
JP2002212052A (ja) * | 2001-01-15 | 2002-07-31 | Hajime Ito | 外用組成物 |
WO2003084556A1 (fr) * | 2002-04-04 | 2003-10-16 | Kaneka Corporation | Procede de fabrication de composition lipidique contenant des composants hydrophobes de glycyrrhiza |
Also Published As
Publication number | Publication date |
---|---|
CN100402047C (zh) | 2008-07-16 |
CN1972700A (zh) | 2007-05-30 |
WO2005084693A1 (fr) | 2005-09-15 |
WO2005084693A8 (en) | 2006-09-21 |
JP2007526260A (ja) | 2007-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ajabnoor et al. | Effect of Trigonella foenum graceum on blood glucose levels in normal and alloxan-diabetic mice | |
EP0501205B1 (de) | Antiphlogistisches Mittel | |
JP2006512330A (ja) | 竹からの抽出のトリテルペノイドサポゲニン化合物の製法と用途 | |
JP2007513868A (ja) | サイトカインモジュレータ及び関係する使用法 | |
TW200538144A (en) | Crude extracts from andrographis paniculata | |
CN105531282A (zh) | 治疗与线粒体功能或抑制PDE4、PDE5和IKK-β相关的病况的源自茶藨子属物种的生物碱组合物 | |
JP6016852B2 (ja) | 動脈硬化の予防又は治療用組成物 | |
TW201321010A (zh) | 具抗關節炎活性的到手香精萃物 | |
JP2009510051A (ja) | 炎症性疾患のための薬草組成物 | |
CN105250366B (zh) | 香青兰提取物及其制备方法和用途 | |
JP4714908B2 (ja) | 沙棘種子抽出物 | |
JPS6120A (ja) | アレルギ−および炎症状態の治療用医薬組成物 | |
TW201902474A (zh) | 用於治療中風及減少神經損傷的化合物及其用途 | |
CN115813833B (zh) | 一种抑菌抗炎生发精华液及其制备方法 | |
JP3977889B2 (ja) | 蕎麦殻抽出物を有効成分とする薬剤 | |
EP2007408A2 (en) | Preventative treatment and remission of allergic diseases | |
CN110898114A (zh) | 一种治疗前列腺增生的药物组合物 | |
JP6076361B2 (ja) | 胃潰瘍の治療用医薬の調製におけるAlbizziachinensis抽出物の応用 | |
JP2015193588A (ja) | 皮膚外用組成物 | |
JP5661309B2 (ja) | 抗肥満剤 | |
CN1246326C (zh) | 化合物菠萝黄酮苷及用途 | |
CN1687092A (zh) | 苍耳子总苷提取物及其制备方法 | |
CN107129478A (zh) | 一种半萜内酯类化合物及其制备方法和应用 | |
DE3723248A1 (de) | Verwendung von thiosulfinsaeurederivaten zur behandlung von entzuendungserkrankungen | |
CN110143989B (zh) | 一种鞣花单宁类α-葡萄糖苷酶抑制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070319 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070319 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070305 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070305 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100909 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101108 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110228 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110307 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140408 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |